Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 97–120 of 150
Ancient Greek and Roman physicians documented longevity patterns through detailed case studies, identifying consistent behavioral practices—meal frequency, diet composition, daily movement, and recovery protocols—that correlated with extended healthspan. These observations predate modern gerontology by nearly two millennia yet align substantively with contemporary longevity research.
This April 2026 roundup surveys emerging research across multiple aging pathways: metabolic dysfunction accelerates aging in sedentary populations, enzymatic depletion drives cellular senescence in fat tissue, meal timing influences biological aging rates, and targeted interventions—from NAD+ restoration to immune mobilization via sauna—show measurable effects on muscle, cognition, and immune function in animal models.
Exercise emerges as the most protective intervention for brain health across the lifespan, with specific performance benchmarks in strength and aerobic capacity serving as measurable proxies for cognitive preservation and longevity. This positions physical capacity as a foundational biomarker that integrates multiple physiological systems rather than a secondary health outcome.
The personal care and longevity industry is shifting from treating visible signs of aging to supporting cellular health upstream, positioning products as maintenance tools for biological function rather than cosmetic fixes. This repositioning extends the customer lifecycle while aligning consumer expectations with the biological mechanisms of aging.
This roundup summarizes March 2026 longevity research across multiple domains: mechanisms linking energy production to neurodegeneration, exercise's effect on brain aging, immunosenescence factors, organ-level aging processes, and the interconnection between microbiome composition, psychological state, and systemic aging. The findings collectively advance understanding of how interventions—from resistance training to nutritional composition to social environment—modulate the rate of age-related decline.
This AMA addresses practical applications of longevity science across disease prevention, body composition assessment, nutritional strategy, movement quality, and habit implementation. The focus is on translating evidence-based tools into sustained clinical and personal practice for extending both lifespan and healthspan.
Capriroso's platform interprets biometric data across weeks and months rather than daily snapshots, helping endurance athletes recognize long-term physiological patterns and make training decisions based on cumulative stress and recovery trends. This approach addresses a gap where abundant data has not improved understanding, potentially extending athletic lifespan through sustainable training practices.
A digital twin technology modeling immune system dynamics in real time enables predictive health outcomes rather than reactive assessment. This shift from static testing to continuous simulation represents a substantive advance in personalized longevity medicine.
Insilico Medicine established an oversight board combining pharmaceutical expertise with longevity science to accelerate AI-driven drug discovery targeting aging hallmarks. The initiative aims to translate experimental compounds into validated therapeutics across fibrosis, oncology, immunology, and metabolic disease.
Allosteric Bioscience is using AI and quantum computing to model molecular mechanisms of aging, targeting pathways including Lamin A, tryptophan metabolism, DNA repair, and mitochondrial function. The approach aims to identify modulators that could reduce age-related disease and extend lifespan.
Insilico Medicine has established an industry-focused Longevity Board to guide AI-driven drug development targeting aging itself rather than individual diseases. The board represents a shift from academic longevity research toward pharmaceutical scalability, with leadership from both the biotech sector and major pharmaceutical companies.
Abu Dhabi is establishing a large-scale health infrastructure combining genomic, phenotypic, and wearable data with AI to enable predictive care and accelerate drug discovery. This represents a shift toward population-level early detection and prevention rather than reactive treatment models.
Human Longevity has launched a mobile application that consolidates clinical data, biomarkers, genetic information, and imaging results into a continuous health record accessible to users. The platform uses AI to identify patterns across longitudinal data, shifting preventive health assessment from episodic annual checkups to real-time risk monitoring and interpretation.
Function's acquisition of Getlabs removes logistical friction from routine health testing by bringing blood draws directly to patients' homes and offices. This operational change addresses a fundamental barrier to consistent health monitoring—the primary prerequisite for sustained, data-driven health optimization.
Biograph's Executive Physical consolidates comprehensive cardiovascular, metabolic, cancer, and neurological screening into a single six-hour appointment using whole-body MRI, advanced CT, and biomarker analysis. This integrated approach identifies significant health findings in approximately 17 percent of participants and demonstrates measurable metabolic improvements in follow-up assessments.
Coordinated global demonstrations are pressuring governments to fund geroscience research and establish regulatory pathways that recognize aging as a treatable medical condition. The rallies highlight a critical gap between accelerating scientific advances in longevity research and stalled policy frameworks that remain anchored to disease-specific treatment models.
Research over the past decade reveals ageism embedded in language patterns across healthcare, media, and social contexts—a finding that directly shapes how patients interpret health messaging and comply with medical guidance. The way aging is linguistically framed influences both psychological resilience and health behavior, making communication precision a measurable longevity factor.
L-Nutra's fasting-mimicking technology platform, validated across 47 clinical trials and 18 university research centers, repositions precision nutrition as essential healthcare infrastructure rather than lifestyle optimization. The company's approach uses targeted nutrient formulations to trigger cellular repair mechanisms—autophagy and metabolic signaling—without the physiological stress of extended fasting, addressing metabolic dysfunction and age-related chronic disease at a systems level.
Life Biosciences' ER-100, a cellular reprogramming therapy, has received FDA clearance for human trials targeting optic nerve disorders. The trial represents a regulatory shift toward rejuvenation-based approaches, potentially positioning cellular age-reversal technologies within mainstream clinical frameworks rather than relegating aging to inevitability.
Colombian centenarians show delayed immunosenescence and younger biological age despite chronological longevity, suggesting that immune system resilience rather than mere longevity is the critical predictor of healthspan. This finding reframes centenarian research toward understanding which mechanisms preserve immune function across decades.
SEMCAP's expansion into beauty and wellness investment signals a structural shift in longevity markets: evidence-backed skincare, haircare, and personalized health products are becoming primary entry points for consumer engagement with aging well, driven by daily rituals and observable body signals rather than clinical diagnostics alone.
Lancôme and Timeline have partnered to develop a skincare line using urolithin A (Mitopure), a molecule that enhances mitochondrial function in skin cells to address aging at the cellular level rather than merely treating visible signs. This represents a shift in luxury skincare from cosmetic coverage to supporting long-term cellular vitality and resilience.
Artificial intelligence is compressing drug discovery timelines from four to five years to approximately fourteen months by automating target identification, molecular design, and clinical trial prediction. This acceleration has direct implications for longevity therapeutics, where speed to market can determine whether interventions reach patients before age-related decline progresses beyond intervention points.
Energy Span reframes fatigue as a quantifiable, systems-level signal of healthspan decline that emerges before conventional biomarkers shift into pathological ranges. This perspective bridges the gap between subjective experience and measurable biology, positioning energy as an early warning system reflecting mitochondrial function, metabolic flexibility, circadian rhythm, and autonomic regulation operating in concert.
